Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACRO-Skin for scalp psoriasis
2019-000215-92Phase 3Completed
- Sponsor
- Bay Pharma
- Start
- Mar 2019
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tacrolimus in psoriasis (2 arms), sponsored by Bay Pharma. Primary endpoint: Primary efficacy endpoint. Started Mar 2019; status: completed.
02
Drugs
tacrolimus
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2019-000215-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000215-92.